modelEfinaconazole
Extends from Pharmacolibrary.Drugs.ATC.D.D01AC19.
Information
| name: | Efinaconazole | |
| ATC code: | D01AC19 | route: | topical |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 36.2 | L |
| clearance: | 16.2 | L/h |
| other parameters in model implementation | ||
Efinaconazole is a triazole antifungal agent primarily indicated for the topical treatment of onychomycosis (fungal infection) of the toenails. It is approved for use in various countries and is currently available as a prescription medication.
Pharmacokinetics
Pharmacokinetic parameters estimated for topical application in healthy adult subjects; limited systemic absorption observed after application to the toenails.
References
Eichenfield, LF, et al., & Guenin, E (2020). Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. Journal of drugs in dermatology : JDD 19(9) 867–872. DOI:10.36849/JDD.2020.10.36849/JDD.2020.5401 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33026753
Gupta, AK, et al., & Cooper, EA (2024). Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis. Expert opinion on pharmacotherapy 25(15) 1983–1998. DOI:10.1080/14656566.2024.2416924 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39394930
Gregoriou, S, et al., & Rigopoulos, D (2022). Novel and Investigational Treatments for Onychomycosis. Journal of fungi (Basel, Switzerland) 8(10) –. DOI:10.3390/jof8101079 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36294644
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)